News GlaxoSmithKline plc LIQUIDNET SYSTEMS

Equities

GSK

GB0009252882

Delayed LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-0.40%	-.--%

04:19pm	GSK’s Rectal Cancer Drug Shows 100% Complete Response Rate in Longer-term Phase 2 Trial	MT
03:28pm	Trending : GSK Shares Tumble on Zantac's Legal Setback	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK’s Rectal Cancer Drug Shows 100% Complete Response Rate in Longer-term Phase 2 Trial	03:19pm	MT
Trending : GSK Shares Tumble on Zantac's Legal Setback	02:28pm	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	02:19pm	MT
GSK Says Cancer Drug Jemperli Shows 100% Clinical Response Rate in Long-Term Data From Mid-Stage Trial	02:03pm	MT
GSK immunotherapy bowel cancer drug works for 100% of patients	02:02pm	AN
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer - Form 6-K	01:59pm	PU
Sector Update: Health Care	01:58pm	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Economic Data	01:36pm	MT
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	01:11pm	BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	01:05pm	PU
GSK to Face Trials Over Zantac Cancer Allegations; Shares Tumble Pre-Bell	12:30pm	MT
GSK : Sell rating from JP Morgan	12:26pm	ZD
GSK : Deutsche Bank reiterates its Buy rating	12:08pm	ZD
FTSE 100 up, while Labour commits to defence	12:00pm	AN
GSK : Goldman Sachs remains Neutral	11:53am	ZD
GSK Shares Plunge After Delaware Ruling Allowing Jury Trials for Zantac Case -- Update	11:21am	DJ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K	11:13am	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K	11:10am	PU
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise	10:41am	MT
European Midday Briefing : Mood Improves on Fed Rate Cut Hopes	10:36am	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK plc : Back on track

May 03, 2024 at 10:17 am

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 04:38 pm